In vivo effects of recombinant interleukin-11 on myelopoiesis in mice

88Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits. © 1993 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Hangoc, G., Yin, T., Cooper, S., Schendel, P., Yang, Y. C., & Broxmeyer, H. E. (1993). In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood, 81(4), 965–972. https://doi.org/10.1182/blood.v81.4.965.bloodjournal814965

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free